Centessa Pharmaceuticals plc, a leading clinical-level pharmaceutical company, has fixed the pricing value of its underwritten public offering of around 11,627,907 American Depositary Shares (ADSs). Every share has attached an ordinary share at a price rate to the public worth $21.50 per ADS. The estimated gross proceeds benefit to Centessa from this granting will be around $250 million before eliminating underwritten commissions, offering expenses payable and discounts by Centessa.
Each ADS sold in the granting were provided by Centessa. The offering is predicted to close on or about 14th November 2025, entitled to customary closing conditions. The company under this offering has given the privilege of a 30-day option to the underwriters to buy an additional 1,744,186 ADSs at reduced underwriting commissions and discounts, and at the said public offering.
Evercore ISI, Guggenheim Securities, Leerink Partners and Jefferies will participate as joint book-running managers throughout this offering's completion. Whereas, LifeSci Capital and Oppenheimer & Co. Truist Securities will be co-lead managers to this granting.
The ADSs are being provided pursuant to a registration statement on Form S-3 filed with the Securities and Exchange Commission (SEC) on 11th September 2024 and were declared effective since the filing date. The accompanying prospectus and preliminary prospectus supplement based on the offering specification will be filed, and a confirmed accompanying prospectus and prospectus supplement of the offering will be filed with the SEC officials. This filed attachment will be accessible on the SEC's website http://www.sec.gov.
The copies of the accompanying prospectus and final prospectus supplement will be available at Leerink, Jefferies LLC, and Guggenheim Securities LLC's official site, address, and online document distribution medium. The company has been involved in various public offerings since May 2021 on public grounds. The impact and performance of many past offerings are highly driven by stock volatility, great initial commitment and their responsible role and responsibility in the funding process.
The specificity of funding leads to comprehensive values and trust among the company, their investors and new interests. The current offering will improve financial health and capitalisation, enhance stock performance and leave a heavy positive impact on the portfolio. The company’s capitalisation thus helps achieve major milestones, allowing the succession of popular existing and new programs. Whereas, analyst sentiments are well aligned with a node of strong buy and a focus on fixed price and an initiative to make it greater than the latest trading prices.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
